Could a Natural Formula Help Children with IBD? New Research Offers Hope

Children living with inflammatory bowel disease (IBD) often face a harder road than adults. The condition, which includes Crohn’s disease and ulcerative colitis, can cause stomach pain, fatigue, and poor growth. For many families, finding the right treatment is a long and difficult process.

While adults now have many effective IBD treatments, children are still catching up. Most new drugs are tested on adults first, and it can take years before they are studied on younger patients. But new research is starting to change that, offering signs of progress for pediatric care.

Three recent studies looked at a natural supplement called CurQD®, which has shown encouraging results in children with IBD who were not responding to conventional drugs. Importantly, the findings highlight CurQD® as an adjunct therapy, designed to complement rather than replace existing IBD medications. While some patients have experienced significant improvement taking CurQD® alone, it is generally recommended as part of a broader treatment plan under medical supervision.

Why Children Are Left Waiting

IBD research has made big advances in adults, thanks to a better understanding of immune pathways and inflammation. But studies in children are more complicated. There are fewer young patients to recruit, and pediatric trials must consider growth, nutrition, and long-term safety.

Because of these challenges, children are often treated with medicines originally made for adults. Doctors must adjust doses and hope for similar results, but children’s bodies can react differently. Many experts say this approach is not good enough, especially since IBD tends to be more aggressive in younger patients.

The goal in pediatric IBD is not only to relieve symptoms but also to stop inflammation early to prevent lasting damage. That is why new, child-specific research like the CurQD® studies is so important.

What the New Studies Found

A study published in the Inflammatory Bowel Diseases Journal tested CurQD® in children with mild-to-moderate ulcerative colitis. Over six weeks, many of the children improved, and some achieved remission. The treatment was well tolerated, showed no major side effects and performed especially well as an add-on therapy that increased the effectiveness of IBD medications.

Another study, published in Frontiers in Pediatrics, evaluated CurQD® among 30 pediatric IBD patients who weren’t responding well to medications. For several weeks, it followed cases from several different medical centers.

The results were impressive. The children’s Pediatric Ulcerative Colitis Activity Index (PUCAI) scores dropped from an average of 31 to 11, showing significant symptom relief. A stool test called fecal calprotectin, which measures gut inflammation, also fell sharply, from about 750 µg/g to 40 µg/g. The treatment was safe, and about two-thirds of the children who stayed on it maintained their improvements many months afterward.

A third study, presented as an abstract in the Inflammatory Bowel Diseases Journal supplement, reinforced these findings and provided additional evidence that CurQD® may be a safe and effective option for pediatric patients. 

A New Direction for Pediatric Gut Health

The CurQD® formulation was developed by Evinature, a company that studies natural compounds for gut and immune health. Evinature’s goal is to combine the best of nature and science by testing traditional ingredients under modern clinical standards.

Curcumin and Qing Dai have both shown anti-inflammatory effects in laboratory studies, but Evinature’s research gives them a new level of credibility. By creating a standardized, clinically tested formula, Evinature helps bring natural therapies closer to mainstream medicine.

Their findings, shared in multiple peer-reviewed publications, show how complementary treatments like CurQD® can work alongside conventional medications to improve outcomes for children.

Why This Matters for Families

Although these studies are small, they represent a positive step toward more holistic, flexible treatment options for children with IBD. They demonstrate that natural, safe adjunct therapies can be studied scientifically in children and still meet rigorous clinical standards.

For parents, that could mean a future where their child’s treatment plan is not limited to pharmaceuticals alone but can include clinically validated natural supplements that support existing medications. For doctors, it provides more data and another way to help young patients reach remission faster and stay there longer.

As research continues and more institutions join this effort, the hope is clear: no child should have to wait years for access to safe, effective IBD treatments.

With science-driven companies like Evinature leading the way in evidence-based natural therapies, the future of pediatric gut health looks brighter than ever.